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Abstract
Many prostate cancers relapse due to the generation of chemoresistance rendering first-line treatment drugs like paclitaxel
(PTX) ineffective. The present study aims to determine the role of miRNAs and Hedgehog (Hh) pathway in chemoresistant
prostate cancer and to evaluate the combination therapy using Hh inhibitor cyclopamine (CYA). Studies were conducted on
PTX resistant DU145-TXR and PC3-TXR cell lines and clinical prostate tissues. Drug sensitivity and apoptosis assays showed
significantly improved cytotoxicity with combination of PTX and CYA. To distinguish the presence of cancer stem cell like
side populations (SP), Hoechst 33342 flow cytometry method was used. PTX resistant DU145 and PC3 cells, as well as human
prostate cancer tissue possess a distinct SP fraction. Nearly 75% of the SP cells are in the G0/G1 phase compared to 62% for
non-SP cells and have higher expression of stem cell markers as well. SP cell fraction was increased following PTX
monotherapy and treatment with CYA or CYA plus PTX effectively reduced their numbers suggesting the effectiveness of
combination therapy. SP fraction cells were allowed to differentiate and reanalyzed by Hoechst staining and gene
expression analysis. Post differentiation, SP cells constitute 15.8% of total viable cells which decreases to 0.6% on treatment
with CYA. The expression levels of P-gp efflux protein were also significantly decreased on treatment with PTX and CYA
combination. MicroRNA profiling of DU145-TXR and PC3-TXR cells and prostate cancer tissue from the patients showed
decreased expression of tumor suppressor miRNAs such as miR34a and miR200c. Treatment with PTX and CYA combination
restored the expression of miR200c and 34a, confirming their role in modulating chemoresistance. We have shown that
supplementing mitotic stabilizer drugs such as PTX with Hh-inhibitor CYA can reverse PTX chemoresistance and eliminate
SP fraction in androgen independent, metastatic prostate cancer cell lines.
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Introduction
Prostate cancer is the second leading cause of cancer related
death in men in the United States [1]. While anti-androgen
therapy is currently the first line of treatment for patients
diagnosed with prostate cancers, most patients will eventually
develop the androgen-independent form of prostate cancers which
is highly metastatic and has poor prognosis [2]. Microtubule
stabilizers such as PTX are effective in treating patients diagnosed
with androgen-independent prostate cancer [3]. While clinical
trials have proven the initial efficacy of taxanes in increasing
survival in prostate cancer patients [4], there are currently few
effective approaches for treating chemoresistant prostate cancers.
Most tumors are heterogeneous and are composed of bulk and
tumor initiating cells (TICs) with the latter forming a distinct
subpopulation in many cancers. TICs are often referred to as
cancer stem cells (CSCs) and are responsible for tumor initiation,
self-renewal, and chemoresistance [5,6]. Many prostate cancers
relapse due to the presence of highly chemoresistant tumor
initiating/cancer stem cells [7,8]. Chemoresistance to anticancer
drugs including PTX, by these cells may be contributed by drug-
efflux pumps which can efficiently remove lipophilic molecules,
including hydrophobic anticancer drugs. This inherent property of
chemoresistant cells is used for identification and isolation of a side
population (SP), which are a type of cancer stem cells. The SP
fraction, initially identified by Goodell, is a small subpopulation of
cells with enriched stem cell activity and are known to demonstrate
distinctively low levels of Hoechst 33342 dye staining [9]. SP
fraction cells have been shown to be insensitive to various
chemotherapeutic drugs [10] owing to their ability in effluxing
chemotherapy drugs (and lipophilic dyes such as Hoechst 33342)
due to the high expression of ATP-binding cassette family, such as
MDR1 (P-glycoprotein) and ABCG2 [11]. Chemoresistant SP
cells will survive and sustain their clonogenicity during initial
exposure to cytostatic drugs, thereby allowing disease recurrence
when therapy is withdrawn. These subsets of CSCs are thus
considered a viable target for improved therapeutic intervention
and preventing chemoresistance and cancer relapse.
The development of chemoresistance through an increase in the
number of cancer stem like cells, including SP fractions has been
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various cancer types. These non-coding RNA molecules can act as
oncogenes as well as tumor suppressor [12,13,14]. Dysregulation
of miRNAs has been implicated in tumorigenesis and drug
resistance as well. Recent work by Cochrane et al. has identified
miRNAs involved in modulating chemoresistance in several
cancers [15].
In our present study, we hypothesized that chemoresistance to
PTX in metastatic prostate cancer cells could be due to the altered
miRNA expression in these cells and that the combination of
antimitotic drug with another small molecule that inhibits CSCs is
likely to be effective in not only reverting chemoresistance by
suppressing CSCs but also target miRNAs involved in chemore-
sistance. Thus, while failure of traditional chemotherapy is due to
a failure to destroy CSCs/SP fractions, a combinatorial approach
is likely to yield better results since the CSC-inhibitor will kill
pluripotent cancer cells and will allow the antimitotic drug (in this
case PTX) to attack bulk tumor cells. Towards this end, we have
combined PTX with cyclopamine (CYA), a natural steroidal
alkaloid which inhibits the Hedgehog (Hh) pathway resulting in
decreased proliferation and increased apoptosis [16]. In recent
years, the Hh signaling pathway has been implicated in the
development and spread of prostate cancer [17,18]. Evidence has
also indicated that Hh signaling supports androgen signaling and
androgen-independent growth in prostate cancer cells in a low
androgen environment [19]. Inhibition of Hh-pathway results in
downregulation of genes involved in stem cell self-renewal as well
as regression of prostate tumor without relapse [20]. Combination
of docetaxel with CYA and epidermal growth factor receptor
(EGFR) inhibitor gefitinib induced greater antiproliferative and
apoptotic effects on SP cell fractions isolated from metastatic
prostate cancer cells than individual drugs [21]. We have recently
demonstrated that adding EGFR-inhibitor lapatinib can enhance
the effectiveness of PTX in inducing apoptosis in a paclitaxel-
resistant, androgen-independent metastatic prostate cancer cells
line DU145-TXR, both in vitro as well as in xenograft tumors [22].
To understand the phenomenon of chemoresistance, in the
present study we have used androgen independent (AI) metastatic
prostate cancer cell lines DU145 and PC3 and their PTX-resistant
versions, DU145-TXR and PC3-TXR, respectively. We have
shown that PTX resistance of prostate cancer cells may be
modulated at the level of miRNAs. We further demonstrate that
combination therapy with CYA and PTX can effectively reduce
cell viability, decrease SP-cell fraction at doses far lower than that
used for CYA monotherapy and impact miRNAs putatively
involved in modulating chemoresistance. Our data indicates that
combination therapy involving supplementation of PTX with Hh-
inhibitors can target specific miRNAs and cancer stem-cell like SP
cell populations at doses that are effective in combination but not
in monotherapy. This approach may represent a better approach
in preventing metastasis and relapse in refractory prostate cancer
since it is less likely to be toxic and will present with far fewer side
effects for the patient, ensuring better compliance and reducing
the chances of a recurrence.
Materials and Methods
Materials
PTX and CYA were purchased from LC Labs (Woburn, MA).
SYBR Green real-time PCR master mix and reverse transcription
reagents were purchased from Applied Biosystems (Foster city,
CA). Goat anti-rabbit P-gp antibody and corresponding secondary
antibody was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). All other chemicals were obtained from Sigma-Aldrich
(St. Louis, MO) and used as received, unless stated otherwise.
Cell lines
The human metastatic prostate cancer cell lines DU145 and
PC3 and their PTX resistant versions DU145-TXR and PC3-
TXR were a kind gift of Prof. Evan T. Keller (University of
Michigan). All cell lines were maintained in RPMI culture media
supplemented with 1% penicillin/ streptomycin and 10% fetal
bovine serum (FBS) (Gibco) in a humidified incubator containing
5% CO2 at 37uC as described earlier [22].
Human Prostate Tissue
Human prostate tissue (cancerous and benign) were obtained
from the Veterans Affairs (VA) Hospital, Memphis, TN following
established protocols and in accordance with the informed consent
waiver provided by the Institutional Review Board (IRB) at
UTHSC and at the VA Hospital. Prostate tissue was taken using
an 18-gauge core needle biopsy gun and a portion of this tissue
was rinsed and either flash frozen in liquid nitrogen and then
stored at 280uC or placed in cold serum-free RPMI media
containing antibiotics for preparing single cell suspensions. Tissues
were classified as malignant or benign based on the diagnosis
made by a pathologist.
Drug sensitivity and apoptosis assays in DU145-TXRCells
To determine the extent of cellular apoptosis following drug
treatments, DU145-TXR cells were plated into 6-well plates
(7.5610
5 cells/well). After 24 h, the media was removed and fresh
media containing varying concentrations of PTX, CYA or their
combinations were added. The cells were then stained with
Annexin-V and Propidium iodide (PI) using the Vybrant
Apoptosis Assay Kit as per the manufacturer’s protocol (Molecular
Probes). Briefly, cells were trypsinized, washed twice with cold PBS
and pelleted by centrifugation at 800 rpm for 5 min. The pellets
were resuspended in 100 ml of 1X Annexin binding buffer and
5 ml fluorescein isothiocyanate (FITC)-Annexin-V. Propidium
iodide (100 mg/ml) was added to each 100 ml of cell suspension.
The stained cells were immediately analyzed by flow cytometry.
DU145-TXR cells were also used to determine the cell growth
inhibition ability of PTX and CYA. Cells (5610
3/well) were
seeded in 96 well cell culture plates and incubated for 24 h to
allow cell attachment. Media was then replaced with fresh media
containing PTX (0.5/1 mM) or CYA (10/25 mM) or combination
(PTX 0.5 mM and CYA 10mM) and incubated further for 48 h at
37uC/5% CO2. Cell viability was then assessed by MTT assay.
For this, media was removed and cells were washed with PBS and
200 ml of fresh media containing 3-(4,5-dimethyl-thiazol-2-yl)-2, 5-
diphenyl tetrazolium bromide (MTT) (0.5 mg/ml) was added
followed by incubation at 37uC/5% CO2 for 4 h. After 4 h, media
was removed and formed formazan crystals were dissolved in
200 ml DMSO and absorbance was measured at 560 nm. Cell
viability was calculated using the following formula:
Cell Viability~
Absorbance of test sample
Absorbance of control
|100
DMSO was used to solubilize PTX and CYA and DMSO
controls were included in all experiments.
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Side population analysis in DU14-TXR and PC3-TXR cell
lines was performed using Hoechst 33342 flow cytometry method.
In brief, adherent cells were trypsinized and washed with
phosphate buffered saline (PBS). Cells (1610
6 cell/ml) were then
suspended in RPMI media supplemented with 2% FBS and 1 mM
HEPES buffer with or without drug solutions (Verapamil, PTX or
PTX+CYA). Hoechst 33342 (5 ml; 1 mg/ml) dye was then added
followed by incubation for 90 min at 37uC. Cells were recovered
by centrifugation and washed several times with PBS to remove
unbound dye and finally suspended in ice cold PBS containing 2%
FBS. SP fraction in clinical samples was analyzed as described
above with additional steps. Briefly, freshly resected prostate tissue
was rinsed, mechanically minced and digested for 4 h at 37uC with
100 U/ml collagenase IV (Worthington Biologicals) in serum free
RPMI. The tissue was frequently pipetted with a 5-ml serological
pipette and at the end of incubation the digest was passed through
an 18.5- gauge needle, centrifuged briefly and the supernatant
sieved through a 100 mm cell strainer to obtain single cell
suspension. Diluted single cell suspensions were then passed once
through 40 mm mesh filter, their viability assessed by trypan blue
staining and kept on ice until analyzed.
Cell Cycle analysis
Flow cytometry was used to determine the percentage of cells in
different growth cycles. Cells (5610
5) obtained after sorting were
washed with PBS and fixed with ethanol (70%) at 4uC overnight
followed by treatment with RNAse (1 mg/ml) and stained with PI
(10 mg/ml). Percentage of cells in different cell cycle phases was
then determined.
In vitro differentiation study
Ability of SP cells to differentiate was determined by culturing
the pure cell fractions in a 6 well plate for 14 days post sorting. SP-
fraction cells from DU145-TXR and PC-TXR (1610
5/well) were
seeded into 6 well plate and allowed to grow in RPMI culture
media supplemented with 10% FBS. After 14 days, Hoechst
staining and SP analysis was done on treated or untreated cell
populations as described above. Gene expression analysis was also
carried out on SP and non-SP cells both before and after-
differentiation.
Western blot analysis
Following treatment, DU145 TXR cells were lysed using RIPA
buffer and total protein concentration was determined using Bio-
Rad RC DC protein assay kit (Hercules, CA). SDS-PAGE was
then performed to resolve the proteins which were then
transferred to Immobilon polyvinylidene fluoride (PVDF) mem-
brane using iBlot dry blotting system (Invitrogen, Carlsbad, CA).
Blocking was done using 5% non-fat dry milk in 1X PBST (PBS
containing 0.05% Tween-20) for 1 h at room temperature.
Membranes were then incubated with primary antibody for
16 h at 4uC. Actin was used as the loading control and target
protein was detected by enhanced chemiluminescence (ECL)
detection kit (GE Healthcare Life Sciences, PA).
Real time RT-PCR
Total RNA was extracted from sorted and unsorted prostate
cancer cells using RNeasy RNA isolation kit (Qiagen, MD),
followed by determination of its quality by Nanodrop 2000
instrument. It was then reverse transcribed into cDNA template as
described before [23]. cDNA (100 ng) was then amplified by real-
time PCR using SYBR Green dye universal master mix on a Light
Cycler 480 instrument (Roche, Indianapolis, IN) using the primers
for genes of interest for forty cycles Relative amount of mRNA
compared to S19 (housekeeping gene) level was calculated using
Crossing point (Cp) values and scaled relative to control samples
set at a value of 1. Results for gene expression in experimental
samples were plotted compared with the control.
MicroRNA (miRNA) profiling and data validation
Total RNA that includes small non-coding miRNA was isolated
from untreated and drug-treated DU145-TXR and DU145 cells
or PC3 and PC3-TXR cells using miRNEasy RNA isolation kit
(Qiagen MD) following manufacturer’s instructions. The same
reagents were used to isolate total RNA from human prostate
tissue. Briefly, flash frozen tissue was suspended in extraction
buffer and subjected to careful disintegration using a hand-held
electric homogenizer for 30s at a low-to-middle speed setting. The
homogenate was centrifuged for 3 minutes at 4uC and the
supernatant was used to extract total RNA. Post-isolation, RNA
quality was determined using a Nanodrop 2000 instrument.
For miRNA profiling studies, SYBR green based pathway-
focused miScript miRNA PCR Array (Qiagen, MD) was used.
The cancer pathway array (catalog number 102ZF) allows the
simultaneous detection of 84miRNAs previously identified in
human cancers, as well as appropriate housekeeping assays and
RNA quality controls. The assay was performed according to the
manufacturer’s protocol. Three hundred nanograms (ng) of total
RNA were converted to cDNA using miScript II RT Kit. Diluted
cDNA was mixed with universal primer and SYBR Green dye and
added to the wells of 96-well plates containing lyophilized primer.
The plates were run on a Roche Light Cycler 480Hinstrument and
the expression of individual miRNAs was analyzed using the
obtained Ct values. The fold change for each miRNA was
calculated by plugging the Cp values into the manufacturer’s web-
based software. DU145 cells or PC3 cells, as well as benign
prostate samples were considered as ‘controls’ in order to calculate
the fold change in DU145-TXR and PC3-TXR cells and
cancerous prostate tissue, respectively. Endogenous controls, RT
negative and positive controls, and genomic DNA contamination
controls were also tested for each array.
Validation of miRNA profiling data was done by real-time PCR
estimation of selected miRNAs. For each of the selected miRNA, a
miScript PCR primer was purchased from Qiagen. This assay
targets only mature miRNAs, not their precursors. As a
normalizer, SNORD6 was used as a housekeeping miRNA.
Briefly, diluted cDNA used for miRNA profiling was used as a
template in the presence of SYBR Green dye, universal primer
and miScript primer. The plate was run as described above and
fold changes in miRNA expression were calculated using the Ct
value of the normalizer control. A similar approach was used to
measure expression of miR200c and miR 34a in DU 145-TXR
cells treated with 0.5 mM PTX+10 mM CYA. After treatment,
total RNA was isolated, reverse transcribed to cDNA and used to
measure miRNA expression as described above.
Statistical Analysis
All values in the figures and text were expressed as the mean 6
SD. The results were analyzed and individual group means were
compared with Student’s unpaired t-test. A p value of at least 0.05
was considered significant and is indicated by an asterisk (*).
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e40021Figure 1. Effect of PTX and CYA combination on viability of PTX resistant DU145-TXR cells. Cells grown in 6-well plates were treated with
A) 0.3% DMSO, B) 0.5 mM PTX C) 10 mM CYA, D) 25 mM CYA, E) 0.5 mM PTX +10 mM CYA for 48h and F) in DU145-TXR cells after different drug
treatments. Subsequently, cells were trypsinized, washed with PBS and stained with Annexin V-FITC and PI before apoptotic analysis by flow
cytometry. A–E are representative plots from three individual experiments. Data in panel F is the quantitation of % cell death and represents mean 6
SD (n=3). *p,0.05 vs. control. For MTT assay (Fig. 1G), cells grown in 96 well plate were treated with indicated concentration of drugs for 48 h.
Subsequently, MTT reagent in PBS was added and incubation was carried out for another 4 h. The resulting formazan product was solubilized in
DMSO and the color intensity was determined using a plate reader. A statistically significant difference (* p value ,0.05) was observed when
combination of 0.5 mM PTX and 10 mM CYA was used. Cell Viability=Atest/AcontrolX100. Data are the means6SD (n=4). PTX, Paclitaxel; CYA,
Cyclopamine.
doi:10.1371/journal.pone.0040021.g001
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Combination of CYA and PTX reduces cell viability and
enhances apoptosis in drug-resistant prostate cancer
cells
The ability of combination chemotherapy to inhibit the growth
of PTX resistant prostate cancer cell line was assessed by cell
viability and apoptosis assay. It was observed that combination of
PTX and CYA significantly (p value,0.05) decreases cell viability
to 40% as compared to either PTX or CYA alone (Fig. 1, panels
A–F). Similar results were obtained in Annexin V cell death assay
wherein combination therapy results in a significantly higher cell
death as compared to single agent chemotherapy (Fig. 1, G). While
a combination of PTX and CYA resulted in nearly 70% of cells
dying, the percent cell death observed with PTX or CYA
monotherapy was 15% and 25% respectively. However, treatment
with 25 mM CYA was significantly more effective than control and
resulted in nearly 40% cell death.
Side Population fractions exist in PTX -resistant prostate
cancer cells and have unique gene expression
Figures 2 and 3 show the SP analysis of prostate cancer cell lines
DU145-TXR and PC3-TXR, respectively as well as the effect of
treatment with PTX and CYA. Control DU145 cells have tiny
amounts of SP (0.2%, Fig. 2A) while PTX resistant cell line
DU145-TXR has ,3.2% of SP cells (Fig. 2B) as indicated by
Hoechst staining (p,0.05 compared to DU 145 cells). In case of
PC3-TXR cells, nearly 2% of viable cells were gated as SP
(Fig. 3A). Verapamil, a known suppressor of efflux pumps was used
in these studies as a control to set up the gates in the FACS dot
plots. As seen in Figures. 2C and 3B, verapamil treatment
significantly reduced SP fractions in DU145-TXR cells to 0.89%
and to 0.6% in PC3-TXR cells. This data is in agreement with the
use of verapamil as a control drug for identifying and gating
Hoechst-light cells in various cancer cells, including prostate
cancer. While treatment with 1 mM PTX for 12 h increased the
SP fraction to 7.8%, treatment with 20 mM CYA, a combination
of CYA and PTX 24 h after removal of PTX for a similar time
decreased SP fraction to , 2% (Fig. 2, panels D, E and F,
respectively) (p,0.05 in all samples). In PC3-TXR cells, the SP
fraction was markedly reduced following treatment with CYA
(Fig. 3C) or CYA and PTX combination (Fig. 3D). Real time RT
PCR analysis indicates higher expression of pluripotency markers
OCT4 and NANOG, and cancer stem cell markers CD133 and
ALDH1 in SP fractions compared to non-SP (NSP) fractions in
both DU145-TXR and PC3-TXR cells. Post-differentiation fate of
SP cells was studied by real time RT-PCR and Hoechst staining
after their isolation and re-culturing. These cells differentiated into
a mix population comprising SP and NSP fractions which differed
in their phenotype (Fig. 4, panels A and B, respectively).
Expression analysis of post-differentiation mixed-populations
indicates reduced transcripts of the ABC-transporter and cancer
stemness marker ABCG2 and higher expression of cell prolifer-
ation marker minichromosome maintenance 7 (MCM7) compared
to undifferentiated SP-fractions (Fig. 4D). Further treatment of
post-differentiation SP populations with 25 mM CYA for 48 h
resulted in the SP fraction significantly decreasing from 15.8%
Figure 2. Analysis of side population (SP) fraction in PTX resistant DU145 TXR cells after treatment with PTX and CYA. A) DU145 cells,
B) DU145-TXR cells, C) DU145-TXR cells treated with verapamil (10 mM, 90 min), D) DU145-TXR cells treated with PTX (1 mM, 12 h), E) DU145-TXR cells
treated with CYA (20 mM, 12 h), F) DU145-TXR cells treated with CYA and PTX (20 mM and 0.5mM, respectively, 12 h). Verapamil was used to gate the
SP fraction in all panels and shown as the percentage of the whole viable cell population. Numerical values indicated are the mean6SD of three
individual experiments. * p,0.05 vs control DU145 cells in (A). PTX, Paclitaxel; CYA, Cyclopamine.
doi:10.1371/journal.pone.0040021.g002
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analysis of the flow sorted SP and NSP cells. It was observed that,
62% NSP cells were in the G0-G1 and 30% in S phase in contrast
to 71.5% and 21% for SP cells, respectively (p,0.05).
Gene and Protein Expression in DU 145-TXR Cells
Expression of P-glycoprotein (P-gp) was assessed by Western
blotting. Proteins were separated by SDS-PAGE and probed with
anti-P-gp antibody to determine changes in protein expression
following treatments. Figure 5A indicates that treatment with
25 mM CYA or a combination of CYA (10 mM) and PTX
(0.5 mM) were equally effective, while treatment with PTX
(0.5 mM) alone was ineffective. Expression of GLI-1 (Hh-pathway
marker), OCT-4 (pluripotency/stem cell marker) and CD133
(cancer stem cell marker) was assessed using real time RT-PCR
method and calculating the fold changes with respect to the Cp
values obtained in DU145-TXR cells. Figure 5B show an
increased expression of GLI-1, OCT-4 and CD133 (p,0.05 for
all genes compared to DU 145 cells).
Profiling of Prostate Cancer Cells Identifies miRNAs
Altered in Chemoresistance
Recent studies have implicated various miRNAs such as let 7,
miR 34a and miR 200c in regulating tumorigenesis and
chemoresistance in humans [12,15]. To establish whether
chemoresistance to PTX in prostate cancer was regulated at the
level of miRNAs, we studied the differential expression of several
miRNAs known to be involved in various human cancers. The
expression of eighty of the most common cancer-related miRNAs
was simultaneously determined by a real time PCR method by
adding template cDNA prepared from DU145, DU145-TXR as
well as PC3 and PC3-TXR cells to 96-well plates containing
miRNA specific primers. A DDCt method was used to calculate
fold changes using PTX-sensitive parental cells as controls.
Figure 6A and B identifies the miRNAs whose expression is
different between PTX-resistant and sensitive prostate cancer cells.
As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c,
34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b,
10a, 17, 125b, 373, 144 and 23b were upregulated in PTX-
resistant cells with respect to parental cells. To confirm that our
findings using this array methodology were accurate and that we
were not reporting false positives, we validated our data by
carrying out miScript primer assays on a select few of the
differentially expressed miRNAs identified using the PCR array.
Figure 6C lists the miRNAs used for data validation. As can be
seen, a very high degree of concordance exists between the fold
changes obtained through the array data and the validating primer
assays. This suggests that our methodology for sample handling
Figure 3. Analysis of side population (SP) fraction in PTX resistant PC3-TXR cells after treatment with PTX and CYA. A) PC3-TXR cells,
B) Cells treated with verapamil (10 mM, 90 min), C) PC3-TXR cells treated with CYA (20 mM, 12 h) or, D) CYA and PTX (20 mM and 0.5mM, respectively,
12 h). The SP fraction, which was eliminated by treatment with verapamil, was gated (P8) in all panels and shown as the percentage of the whole
viable cell population. Numerical values indicated are the mean6SD of three individual experiments. * p,0.05 vs control DU 145 cells (A). PTX,
Paclitaxel; CYA, Cyclopamine.
doi:10.1371/journal.pone.0040021.g003
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the validity of our approach.
To confirm that combination therapy is effective in targeting
miRNAs involved in modulating chemoresistance, DU145-TXR
cells were treated with a combination of PTX (0.5 mM) and CYA
(10 mM) for 48 h and expression of miRs 200c and 34a was
determined. Figure 6D demonstrates that combination therapy at
concentrations effective in reducing cell viability and inducing
apoptosis in PTX-resistant prostate cancer cells also upregulated
two anticancer miRNAs involved in decreasing the spread of
prostate cancer (34a) and increasing sensitivity to drugs like PTX
(200c). While expression of miRNA 200c increased approximately
4 fold after treatment, there was nearly a 3-fold increase in
miRNA 34a expression (p,0.05 compared to untreated control
cells).
Expression Analysis of Gene Targets of miRNAs 200c and
34a
Since miRNAs act by either repressing or cleaving their target
mRNAs, we carried out gene expression analysis of several known
downstream targets of several miRNAs, including miR200c and
34a identified in our cell and tissue miRNA arrays. Figure 7
delineates these target genes and their expression patterns in
DU145-TXR cells compared to DU145 cells. As can be seen,
there is upregulation of miR 200c target genes like VIMENTIN
(2.5 fold), TUBB-3 (5 fold), ZEB 1 (5 fold), and miR 34a targets
like CD44 (6 fold) and SIRT1 (2.5 fold) while the expression of
another miR200c target E-CADHERIN was downregulated in
DU145-TXR cells. In addition, gene targets of several miRNAs
differentially expressed in this study were altered in DU145-TXR
cells as well. These include DNMT1 (1.5 fold), BAK1 (2.4 fold)
and PUMA (2.5 fold) downregulation.
Figure 4. Post differentiation fate of side population fractions from DU145-TXR cells. After flow sorting, pure SP cells were plated and
allowed to differentiate for 2-weeks. Representative photomicrographs of SP (A) and NSP cells (B) are shown with more SP cells possessing a
fibroblastic, elongated phenotype compared to NSP. Real time RT-PCR was used to confirm higher expression of stem cell markers OCT 4 and NANOG
and cancer stem cell markers CD133 and ALDH1 (C). Similar method was used to show higher expression of pluripotency and efflux marker ABCG2
and lower expression of MCM7 transcripts in initial SP cells (SP), compared to mixed populations post-differentiation (DIFF) where decreased ABCG2
and increased MCM7 levels were observed (D). One set of cells was also treated with 25 mM CYA for 48h. Subsequently, cells were trypsinized and re-
stained with Hoechst dye and analyzed by flow cytometry. Post-differentiation, cells derived from flow sorted SP cells had higher percentage of SP
cell fractions than obtained previously from non-sorted DU145-TXR cells. CYA treatment significantly reduced (p,0.001 vs. control) the percentage of
SP fraction cells from 15.8 (62.1) % (Panel E) to 0.66(0.09) % (Panel F). Representative dot plots from three individual experiments are provided. Data
represents mean 6 SD (n=3).
doi:10.1371/journal.pone.0040021.g004
Table 1. Cell Cycle distribution of SP and non-SP Cells
following cell sorting.
DU 145 TXR cells Cell Cycle Distribution (%)
G0-G1 S G2-M
SP 71.561.5* 2162.4* 7.562.7
Non-SP 62.0862.3 3061.6 7.9263.2
SP and non-SP fractions were fixed overnight in ice cold 70% ethanol as
indicated in ‘Methods’. Subsequently, they were washed with PBS and stained
with a solution of propidium iodide (PI) and RNAase A before flow cytometry. A
statistically significant difference was observed in the cell cycle distribution.
*p,0.05 vs. Non-SP cells.
doi:10.1371/journal.pone.0040021.t001
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We also carried out SP fraction analysis and cancer miRNA
profiling in clinical prostate tissues. SP fraction was analyzed by
Hoechst staining as described earlier. Nearly 1% of total viable
cells in prostate cancer tissue were SP cells (Fig. 8A), closely
mirroring our findings in PTX-resistant prostate cancer cell lines.
miRNA profiling of cancer tissue from a second patient was also
carried out. For data analysis and subsequent validation, we used
benign prostate tissue from a third patient biopsy as a normal-
ization control. Similar to our results described earlier, we were
able to identify several miRNAs such as miRs 17, let71, 31a, 193b,
29b, 155, let 7d, 9, 125b and 30 as being upregulated while miRs
145, 205, 34a, 126, 200c, 27b, 99a and 152 were downregulated in
prostate cancer tissue (Fig. 8B). Further, there are a number of
miRNAs that are common to our tissue and cell arrays in the
present study. For example, not only are miRs 155, 29b, 34a,
200c, 193b and 17 differentially expressed in cell line miRNA
analysis, their expression patterns too match those seen in the
tissue arrays, thereby further validating our data obtained from
chemoresistant cancer cells.
Discussion
Advanced prostate cancer is usually treated with drugs like
paclitaxel and docetaxel which eradicate the bulk of cells within
the tumor. This therapeutic regimen often leads to chemoresis-
tance for which few treatment strategies currently exist. Most
tumors are heterogeneous and are composed of bulk cancer cells
and a small population of pluripotent stem cells that are capable of
self-renewal, are chemoresistant and capable of maintaining the
tumor [5,7]. These cancer stem cells (CSCs) are the reason why
most chemotherapy drugs eventually lose their efficacy. We have
recently shown that combining the antimitotic drug PTX with an
Her-2 inhibitor, such as lapatinib can reverse chemoresistance
[22]. There is some evidence that lapatinib exerts its anticancer
effects in part by targeting the niche population of CSCs [24].
In recent years, inhibitors of Hh pathway such as CYA have
been investigated for treating various malignancies as dysregula-
tion of this pathway is a key step in generation and sustainment of
cancers [17,19,20]. In prostate cancer too, there is evidence that
Hh-pathway is upregulated [25]. Androgen independent prostate
cancer cells such as DU145 and PC-3 have higher expression of
Hh pathway members than androgen-dependent cells such as
LnCaP [26]. Higher Gli-1 gene expression in PTX resistant
DU145-TXR cells (Fig. 6) was observed compared to non-resistant
parental cells. This prompted us to study the effect of combining
CYA with PTX to treat the PTX chemoresistant. Treatment of
DU145-TXR cells with 0.5 mM PTX and 10 mM CYA reduced
cellular proliferation and cell viability while apoptosis, as measured
by AnnexinV-FITC staining, increased significantly after 48 h of
treatment (Fig. 1). In accordance with our previous observations
[22], 0.5 mM PTX alone was not effective in reducing viability of
DU145-TXR cells or inducing significant levels of apoptosis. Even
though CYA at 25 mM decreased cell viability significantly, this
reduction was still less than that achieved with lower concentration
of drugs used in combination therapy. This ability to decrease
proliferation of cancer cells while utilizing significantly reduced
amounts of highly toxic drugs is a potential advantage for
improved chemotherapy.
Many prostate cancers relapse due to multi-drug resistance
(MDR) caused by the over-expression of ATP-binding cassette
transporter proteins. These transporters actively efflux chemo-
therapeutic drugs from tumor cells and decrease the intracellular
drug concentration [8,27]. Therefore, modulation of MDR
transporters is a promising approach to overcome MDR
[28,29,30]. We have determined the effect of monotherapy with
PTX or CYA, and their combination on the P-gp protein
expression which is one of the major efflux pump systems involved
in chemoresistance [31,32]. Figure 5 indicates that treatment with
a combination of PTX and CYA (0.5 mM and 10 mM, respec-
tively) was able to downregulate P-gp protein expression. Thus,
supplementing PTX with CYA can eliminate the chemoresistance
of androgen independent prostate cancer cells by possibly
suppressing MDR and decreasing P-gp expression.
In addition to the P-gp system, chemoresistance is regulated by
various other mechanisms, including cancer stem cells which are
Figure 5. Effect of PTX and CYA on P-gp expression in DU145-TXR cells. Following treatment, with various drugs as described, total protein
was extracted and separated by SDS-PAGE before probing with P-gp antibody. Actin was used as a loading control. A combination of 0.5 mM PTX and
10 mM CYA was more effective in downregulating P-gp expression in drug-resistant prostate cancer cells than monotherapy with either CYA or PTX at
10 and 0.5 mM concentration. P-gp downregulation with 25 mM CYA was nearly similar to that obtained by combination therapy. (B) Expression of Hh
pathway and stem cell marker genes in DU145-TXR cells. Total RNA was extracted from cells and reverse transcribed to cDNA. Real time RT-PCR was
carried out using SYBR Green chemistry and Ct values thus obtained were used to calculate the fold change. Drug resistant DU145-TXR cells have
higher expression of all three genes tested. PTX sensitive DU145 cells were used as control and gene expression values for DU145-TXR cells were
normalized with respect to the control values. *p,0.05 vs. control.
doi:10.1371/journal.pone.0040021.g005
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drugs. Many current techniques used for characterization of these
stem cells rely on the presence of cell surface markers such as
CD133 and CD44 which were used to isolate these cells using a
flow cytometry approach [5,33]. However, this approach suffers
from the fact that during processing, including trypsinization,
many of these surface markers are cleaved and therefore not
available for antibody binding. Further, CD 133 is not a reliable
marker for isolating CSCs as its expression may not be restricted to
cancer stem cells and that even CD 133
2 cells can initiate
tumorigenesis [34]. For this reason, the vital dye Hoechst 33242
was used in the present study for separating SP from main
population of cancer cells. The SP fractions are a subpopulation of
CSCs which were first identified in a hematopoietic stem cell
isolation procedure [9]. These cells have a unique fluorescence-
activated cell sorting (FACS) signature and can be separated by a
flow cytometer with a UV laser as they are distinct from cells that
take up the Hoechst 33342 dye. The SP fraction is capable of
sustained expansion ex vivo and can generate both SP and non-SP
progeny. To understand the mechanism of chemoresistance in
chemoresistant prostate cancer cells, we hypothesized that these
cells are likely to contain a higher percentage of cells that are
chemoresistant and therefore have increased ability to efflux
chemotherapy drugs like PTX. Staining with Hoechst dye resulted
Figure 6. miRNA profiling of prostate cancer cells and effect of combination therapy on miRNA expression. Total RNA including
miRNAs was isolated from DU145-TXR and DU145 cells (A) or PC3 and PC3-TXR cells (B) using miRNEasy RNA isolation kit. SYBR Green based pathway-
focused miScript miRNA PCR Array (Qiagen, MD) was used for miRNA profiling studies. The plates were run on a Roche Light Cycler 480H instrument
and the expression of individual miRNAs was analyzed using the obtained Cp values and the DDCt method. Table in the insert (C) confirms validation
of miRNA profiling data by miScript primer assay. Validation of miRNA profiling data was done by a SYBR Green based real time RT-PCR assay of
selected miRNAs. As a normalizer, SNORD6 was used as a housekeeping miRNA. (D) Efficacy of combination therapy on restoration of miR 200 c and
34a was determined by treating DU145-TXR cells with PTX (0.5 mM) and CYA (10 mM)combination for 48 h after which total RNA was extracted,
converted to cDNA and used as template for miScript primer assay for determining expression of miRNAs 200c and 34a. Untreated DU145-TXR cells
were used as control for calculating fold change after a SYBR Green real time RT-PCR assay. Data represents mean 6 SD (n=3). * p,0.05 vs. untreated
control.
doi:10.1371/journal.pone.0040021.g006
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gated region in Fig. 3 and P8 gated region in Fig. 4 is lightly
stained compared to other cells. These lightly stained cells are the
SP fraction which constitutes approximately 2–4% of total viable
cells. In contrast, the parental PTX-sensitive DU145 cells had only
0.2% cells in the P4 region, thereby confirming our hypothesis of a
distinct cell population with the ability to efflux hydrophobic drugs
effectively, thereby inducing chemoresistance. Treatment with
verapamil, an inhibitor of calcium gated channels, and known
suppressor of cancer stem cells [35] significantly reduced SP
fraction thereby confirming that the population being gated is
indeed related to CSCs. It is a known fact that in relapsed tumors
and metastatic cancers, there are an increased percentage of
cancer stem cells and SP fractions. In the present case also,
treatment of DU145-TXR cells with 1 mM PTX actually
increased SP fraction to nearly twice that observed in untreated
samples (7.7% vs 3.4%). These observations are supported by
several lines of evidence that indicate the role played by Hh-
pathway in maintaining stem cells, including cancer stem cells in
various tumors [36,37]. Further, treatment with Hh-inhibitors can
reduce or eliminate tumorigenic stem cells [37,38,39]. The present
data indicates that there is more expression of OCT 4, a marker
for self-renewal and pluripotency and CD133, a general marker
for cancer stem cells [5] in DU145-TXR cells. This emphasizes
the potential reservoir of CSC like cells mixed with bulk cancer
cells in the chemoresistant cell line. From the theory of biogenesis
of CSCs, it is clear that SP fraction have the potential for
asymmetric differentiation and can give rise to non-SP fractions
which will go on to form the bulk tumor cells [5,40]. To verify this
theory in prostate cancer cells, pure SP and NSP fractions were
isolated by flow sorting recultured and photographed. Fig. 4A and
B are representative micrographs of isolated SP cells and NSP
fractions. As can be seen, SP fraction has more elongated cells with
typical fibroblastic phenotype while NSP cells were more rounded.
Further, compared to the non-SP, the SP cells from PTX-resistant
versions of both DU 145 and PC3 cells had higher gene expression
of pluripotency markers OCT4 and NANOG [41] and increased
expressions of cancer stem cell markers ALDH1 and CD133
(Fig. 4C). This is not surprising since CSCs, including SP fractions
are capable of self-renewal and can therefore persist in cultures
such as those established after flow-sorting. Comparison of
expression of ABCG2 and MCM7 transcripts also differed
significantly between SP fraction and their progeny mixed
populations. While expression of efflux pump ABCG2 was higher
in SP cells, proliferation marker MCM7 [42] was highly expressed
in post-differentiated cells compared to initial SP cells suggesting
the propensity of these cells for reduced proliferation. Even after
differentiation, the number of SP-fraction cells was very high
(almost 16%) which vanished after treatment with a high
concentration of CYA (25 mM) for 48 h suggesting that suppres-
sion of Hh-pathway may be playing a role in their persistence and
maintenance (Fig. 4E and F, respectively). Isolated SP and NSP
fractions were also used to confirm the cell cycle stages. We have
shown that more SP cells were in G0/G1 phase than non-SP cells
(Table 1). This is in accordance with our gene expression data and
studies from other workers who have demonstrated that the
inherent stem cell like properties of SP population include a
propensity for quiescent phase [21,40]. This may be the reason
CSCs can bypass the G1/S checkpoint and thus maintain their
ability for self-renewal and remain pluripotent.
Recent studies have demonstrated that dysregulation of various
miRNAs is associated with the etiology, metastasis and prognosis
of various cancers including prostate cancer [13,14]. So far, nearly
50 miRNAs have been reported to be significantly expressed in
human prostate cancer but only a few have been linked directly to
the pathology and progression of prostate cancer [43,44]. To
confirm the hypothesis that chemoresistance to PTX involves
differential expression of miRNAs, a focused profiling of miRNAs
known to be involved in various malignancies was carried out in
DU145-TXR and PC3-TXR cells (Fig. 6A and B, respectively).
Several miRNAs involved in prostate cancer and other malignan-
cies were differentially expressed in chemoresistant prostate cancer
cells. Significant among these include miR200c, miR34a and
miR29b, all of which are downregulated in DU145-TXR cells.
Figure 7. Real time RT-PCR identification of gene targets of miRNA in DU145-TXR Cells. Several genes involved in cancer related
biological processes and known targets of differentially expressed miRNAs in our study are altered in PTX resistant DU145 TXR cells. Following RNA
extraction and SYBR Green based real time RT-PCR using specific gene primers, Cp values were calculated and resistant DU145 cells were used to
normalize the expression of individual genes. Data represents the mean 6 SD (n=3).
doi:10.1371/journal.pone.0040021.g007
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which shows that miR34 is downregulated in prostate cancer and
its experimental replenishment in cultured cells prevents metastasis
and invasion [45]. miRNA200c, which is downregulated in
DU145-TXR cells, is a tumor-suppressor miRNA known which
maintains ‘epithelialness’ of cancer cells by preventing EMT and
the assumption of an aggressive chemoresistant mesenchymal
phenotype. A recent study by Cochrane et al. confirmed reduced
expression of miR200c as being responsible for chemoresistance to
microtubule stabilizers (such as taxanes) in endometrial, breast and
ovarian cancer cells. In multi-drug resistant cancer cells, restora-
tion of miR200c levels by transfection of its mimic restored
chemosensitivity to PTX [15]. This observation is further
supported by evidence that the loss of miR200c expression results
in a highly aggressive, mesenchymal and chemoresistant pheno-
type in lung cancer cells [46]. In view of the findings described
above, we decided to confirm the effect of our combination
therapy on the expression of miR200c and miR34a (Fig. 6D).
After treatment with 0.5 mM PTX and 10 mM CYA for 48 h, the
expression of both miRs 200c and 34a were increased significantly,
compared to non-treated TXR cells. It is therefore feasible that
this increase in the levels of these miRNAs due to the combination
therapy is responsible for the increased apoptosis and decreased
cell proliferation (Fig. 1).
Expression analysis of select genes which are known targets of
differentially expressed miRNAs, including miR200c and 34a was
carried out to further support our miRNA data. [47]. Figure 7
details some miRNA target genes which are altered in DU145-
TXR cells compared to the parental DU145 cells. SIRT-1 is
suppressed by miR34a and is upregulated in prostate cancers
following loss or downregulation of miR34a [48]. In wild type
cells, downregulation of SIRT-1 by miR34a results in increased
Figure 8. SP fraction analysis and miRNA profiling of clinical prostate tissues. (A) Human prostate cancer tissue was converted to single cell
suspensions as described in ‘Methods’. Cells were stained with Hoechst dye and analyzed as described previously. Nearly 1% of total viable cell
population was gated as the SP fraction. (B) Total RNA was isolated from another set of human prostate tissues (cancer and benign) using miRNEasy
RNA isolation kit. SYBR Green based pathway-focused miScript miRNA PCR Array (Qiagen, MD) was used for miRNA profiling studies. The plates were
run on a Roche Light Cycler 480H instrument and the expression of individual miRNAs was analyzed using the obtained Ct values and the DDCt
method. The fold changes in the tumor tissues were normalized with respect to the benign prostate tissue. (C) Table in the insert confirms validation
of miRNA profiling data by miScript primer assay. Validation of miRNA profiling data was done by RT-PCR estimation of selected miRNAs200c, 34a and
29b. SNORD6 was used as a housekeeping miRNA for data normalization.
doi:10.1371/journal.pone.0040021.g008
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cells may be due this loss of miR34a. CD 44 is also a surface
marker for CSCs [5] and it stands to reason that it will be
upregulated in a cell line where miR34a is downregulated and
where SP fraction cells are found in higher numbers. Downreg-
ulation of miRNA200c leads to an EMT transformation which is
characterized by a loss of E-CADHERIN (E-CAD) and upregula-
tion of VIMENTIN (VIM) [15]. In aggressively metastatic cell
lines from breast, ovarian and endometrial cancers, E-CAD levels
are suppressed by ZEB-1 which is upregulated as a result of
suppression of miR200c. Downregulation of miR200c also
increases the protein and gene levels of TUBB-3. It has been
suggested that decreased protein levels of TUBB-3 protein
correlate to increased cell death in response to microtubule-
targeting agents such as PTX. DNMTa1 which is also upregulated
is a target of miR29b and is regulated by global hypomethylation.
Loss of miR29b results in upregulation of DNMTa1 at protein and
gene levels in aggressive cancer cells [50] such as seen in the
present study. Bak-1 which is downregulated in DU145-TXR cells
is a target of miR125b, a known oncomir which confers
chemoresistance to PTX in breast cancer cells through suppression
of Bak-1 gene [51]. Another target of miR125b is PUMA which is
a proapoptotic gene and is suppressed when miR125b is
overexpressed in cancer cells [52].
Finally, to correlate and extrapolate the above findings to
clinical studies, SP fraction analysis (Fig. 8A) and miRNA profiling
of prostate cancer tissues (Fig. 8B) was performed. Presence of
distinct SP fractions in clinical prostate cancer tissue is supportive
of our cell culture data. Further, as several miRNAs which are
verifiably altered in PTX-resistant cell lines, such as miR200c and
miR34a, are similarly modified in a clinical prostate cancer
sample, our hypothesis and the overall approach taken to confirm
it are strengthened substantially
Conclusion
We have established that chemoresistance to PTX in DU145-
TXR and PC3-TXR cells is possibly regulated by miRNAs which
are differentially expressed when the PTX sensitive cell line is
transformed to a resistant phenotype. miRNAs are known to
regulate cancer stem cells, chemoresistance and EMT since CSCs
possess a mesenchymal phenotype that allows them to be invasive.
This crosstalk between miRNAs, cancer stem cells and the
resulting physiologic processes such as metastasis and chemoresis-
tance is explained in the schematic in Figure 9.
The present study thus suggests a strategy to restore chemo-
sensitivity to drug-resistant cancer cells, thereby ensuring that
cancers do not relapse due to generation of CSCs in tumors.
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